Dermal Cell News Volume 6.28 | Aug 10 2020

May 12, 2022

DCN 6.28 | Aug 10

Dermal Cell News by STEMCELL Technologies

Vol. 6.28 – 10 August, 2020

TOP STORY

Mechanisms of Stretch-Mediated Skin Expansion at Single-Cell Resolution

Using a multidisciplinary approach that combines clonal analysis with quantitative modelling and single-cell RNA sequencing, scientists showed that stretching induced skin expansion by creating a transient bias in the renewal activity of epidermal stem cells, while a second subpopulation of basal progenitors remained committed to differentiation.
[Nature]

Full Article

6aadb653-5361-4065-9810-7075637bb1f3_ON701EPI-Organoids-Wallchart-Ads-728x90

PUBLICATIONSRanked by the impact factor of the journal

DERMAL STEM CELLS & TISSUE REGENERATION

Distinct Regulatory Programs Control the Latent Regenerative Potential of Dermal Fibroblasts during Wound Healing

Using complementary fate-mapping approaches, researchers showed that hair follicle mesenchymal progenitors made limited contributions to wound repair. In contrast, extrafollicular progenitors marked by the quiescence-associated factor Hic1 generated the bulk of reparative fibroblasts and exhibited functional divergence, mediating regeneration in the center of the wound neodermis and scar formation in the periphery.
[Cell Stem Cell]

Abstract Graphical Abstract

Cutibacterium Acnes Regulates the Epidermal Barrier Properties of HPV-KER Human Immortalized Keratinocyte Cultures

Real-time cellular analysis showed that depending on the keratinocyte differentiation state, the applied C. acnes strains and their dose, the measured impedance values change, together with the expression of selected tight junction proteins.
[Scientific Reports]

Full Article

SKIN CANCERS & DISORDERS

Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma

Targeting melanosomal proteins or oncogenic CDK4^R24C by adoptive cell transfer of the same epitope-specific CD8⁺ T cells revealed diverse genetic and non-genetic immune escape mechanisms.
[Immunity]

Abstract Graphical Abstract

Reversal of Pre-existing NGFR-Driven Tumor and Immune Therapy Resistance

Researchers chronically exposed patient-derived melanoma cell lines to differentiation antigen-specific cytotoxic T cells and observed strong enrichment of a pre-existing NGFR^hi population.
[Nature Communications]

Full Article

Circ-GLI1 Promotes Metastasis in Melanoma through Interacting with p70S6K2 to Activate Hedgehog/GLI1 and Wnt/β-Catenin Pathways and Upregulate Cyr61

Scientists found that circ-GLI1 exacerbated the metastasis and angiogenesis of melanoma by upregulating Cyr61 via p70S6K2-dependent activation of Hedgehog/GLI1 and Wnt/β-catenin pathways.
[Cell Death & Disease]

Full Article

Dynamic Control of Tumor Vasculature Improves Antitumor Responses in a Regional Model of Melanoma

Dynamic control of tumor vessels in C57BL/6 mice bearing B16 melanoma was performed using volume expansion followed by phenylephrine. Intravital microscopy was used to observe changes directly in real time.
[Scientific Reports]

Full Article

REVIEWS

EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment

The authors present an update of the specific roles of epithelial–mesenchymal transitions in melanocyte differentiation and melanoma progression. As major regulators of phenotype switching between differentiated/proliferative and neural crest stem cell-like/invasive states, these factors appeared as major drivers of intra-tumor heterogeneity.
[Cancers]

Full Article

INDUSTRY AND POLICY NEWS

FDA Approves Genentech’s Tecentriq Plus Cotellic and Zelboraf for People with Advanced Melanoma

Genentech announced that the FDA approved Tecentriq^® plus Cotellic^® and Zelboraf^® for the treatment of BRAF V600 mutation-positive advanced melanoma patients.
[Genetech]

Press Release

Checkmate Pharmaceuticals Granted FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade in the Treatment of Certain Types of Metastatic or Unresectable Melanoma

Checkmate Pharmaceuticals, Inc. announced that the FDA granted Fast Track designation to its product candidate, CMP-001, in combination with a programmed death receptor 1 (PD-1) blocking antibody for initial treatment of patients with unresectable stage III or stage IV melanoma; and treatment of patients with unresectable or metastatic melanoma refractory to prior anti-PD-1 blockade.
[Checkmate Pharmaceuticals (BusinessWire, Inc.)]

Press Release

FEATURED EVENT

Mechanisms of Stretch-Mediated Skin Expansion at Single-Cell Resolution

Distinct Regulatory Programs Control the Latent Regenerative Potential of Dermal Fibroblasts during Wound Healing

Cutibacterium Acnes Regulates the Epidermal Barrier Properties of HPV-KER Human Immortalized Keratinocyte Cultures

Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma

Reversal of Pre-existing NGFR-Driven Tumor and Immune Therapy Resistance

Circ-GLI1 Promotes Metastasis in Melanoma through Interacting with p70S6K2 to Activate Hedgehog/GLI1 and Wnt/β-Catenin Pathways and Upregulate Cyr61

Dynamic Control of Tumor Vasculature Improves Antitumor Responses in a Regional Model of Melanoma

EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment

FDA Approves Genentech’s Tecentriq Plus Cotellic and Zelboraf for People with Advanced Melanoma

Checkmate Pharmaceuticals Granted FDA Fast Track Designation for CMP-001 Combined with PD-1 Blockade in the Treatment of Certain Types of Metastatic or Unresectable Melanoma

Transcription and Chromatin

> See All Events

Senior Laboratory Research Scientist – Cancer Dynamics

Postdoctoral Fellow – Immune and Stem Cell Engineering

Faculty Positions – Regenerative Medicine

Postdoctoral Positions – Cancer Genomics/Computational Biology

Postdoctoral Fellow – Novel Melanoma Therapies (Villanueva Lab)

> See All Jobs